TORNTPHARMNSE27 September 2022

Torrent Pharmaceuticals Limited has informed the Exchange about Investor Presentation

Torrent Pharmaceuticals Limited

27th September, 2022

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 (BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on acquisition of Curatio Health Care (I) Private Limited

The presentation on acquisition of Curatio Health Care (I) Private Limited to be made to Investors / Analyst is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: As above

___________________________________________________________________________________ TORRENT PHARMACEUTICALS LIMITED CIN: L24230GJ1972PLC002126 Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100, www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com

Building Leadership in a High Growth Therapy Area

27th September 2022

1

Curatio At A Glance

Key Brands

Brands

17+ Year of operation

95% Dermatology Sales

~Rs 224* Cr FY’22 Sales

50+ Total Brands

13 Brands leader in the covered market

~Rs 275 Cr FY23E Sales

~600 MRs Sales Force

900+ Distributors

Online sales channel

* 222 cr India Business

Acquisition Positions Torrent as Second largest player in Cosmetic Dermatology

Torrent pharma to acquire 100% of Curatio India Pvt Ltd. having operations in India, Nepal, Srilanka & Philippines

84% contribution from Cosmetic dermatology; non regulated market

Portfolio of 50+ brands in Dermatology therapy

Include leading brands like Tedibar, Atogla, Spoo, Permite, Perlice etc. Top 10 brands contribute 75% to the portfolio

Overlap limited to ~10%

Supply extension of current manufacturing arrangements for 3 Years

79% contribution from Chronic/sub chronic portfolio (IPM 54%)

7% portfolio under NLEM (IPM 16%)

Potential access to OTx market through India’s leading baby product brand Tedibar; Spoo & Atogla

Growth Opportunity: Derma is a High Growth Therapy Area

Sales 222 Cr

171 Cr

131 Cr

2019-20

2021-22

H1

• As per FY’22 Curatio has registered sales of

222 Cr with 25% Gr

• Derma is the key therapy for Curatio contributing 95% in it’s overall sales

• 84% of the derma therapy sales contributed

by high growth cosmetic dermatology

Therapy

% 5

t s e R

% 5 9

a m r e D

Cosmo Derma

Medical Derma

% 4 8

% 6 1

% 8 6

% 2 3

CURATIO

IPM

H1 on estimated basis

*Source: AIOCD MAT Aug’22

Tedibar (Rs. 76 cr sales FY22, YTD August growth 15%)

670 L

120 L

25 L

<15Y Age Group

Atopic Dermatitis Incidence

Existing Market Penetration

80% potential market is not yet served

Condition addressed • Dryness and irritation associated with atopic dermatitis • Maintains the pH balance of 5.5 which can get elevated to as

high as 6.5 in atopic dermatitis

Key Differentiators •

India’s leading low pH cleansing bar –made from synthetic detergent to maintain pH

• High Gross Contribution product with significant headroom for

increase Long Term Usage - Typically start using as a toddler and may continue

Growth Opportunity: Cosmetic Dermatology is the Key Driver of Derma Growth

CAGR : 10%

IPM

174k Cr

65K Cr

CAGR : 13%

Derma

GP

Specialist

Dermat

GP

Specialist

Dermat

3%

39%

58%

11.5K Cr

3.3K Cr

40%

30%

30%

2012

2022

2012

2022

• CAGR of cosmetic dermatology is 1.6 times than IPM

• Derma TA value grew by 3.5 times whereas

cosmetic dermatology grew by 4.5 times vs IPM 2.7 times

Cosmetic Dermatology

CAGR : 16%

3.6 K Cr

Expanding Torrent presence in high growth area

0.8 K Cr

• Cosmetic dermatology is more specialist focus business;

62% dermatologist contribution in total Rx. Matching with Torrent current DNA

2012

2022

GP

Specialist

Dermat

15%

62%

23%

*Source: AIOCD MAT Aug’22

Overview: Curatio Brands can Expand the Covered Market

Torrent

4286Cr

Curatio (India)*

222 Cr

Torrent + Curatio

4508 Cr

§ Curatio India has reported sales of 222 Cr in FY22. FY23 E growth is 25%

§ Top 10 brands contributing 74% of the total sales

§ Top 3 brands contribute more than 50% of the total sales

Tedibar

Atogla

Spoo

B4 Nappi

• Mkt Size: 1477 Cr | CAGR 2Y: 11% • Rank 2nd

• Mkt Size: 1300 Cr| CAGR 2Y: 11% • Rank 5th

• Mkt Size: 174 Cr | CAGR 2Y: 10% • Rank 1st

• Mkt Size: 1466 Cr | CAGR 2Y: 11% • Rank 3rd

* FY22 India Business Internal figures

Rank: AIOCD MAT Aug’22; Market size & Growth: Bain & company estimate

Top 5 brands contribute ~60% to the portfolio

Tedibar

95

76

25%

Atogla

32

27

20%

Permite/Perlice

17

14

21%

21-22

22-23 E

21-22

22-23 E

21-22

22-23 E

Spoo

11%

14

13

Clinmiskin

10

8

19%

Top 5 Brands

167

137

22%

21-22

22-23 E

21-22

22-23 E

21-22

22-23 E

21-22: Internal Sales; 22-23 E: Estimated sales based on YTD’Aug

Key Brands of Curatio part of high growth market with high market share

11%

<10% MS%

22%

% R G A C t k M % 0 1 >

% R G A C t k M % 0 1 <

52%

>10% MS%

15%

% contribution to Sales

Top Brands on A High Growth Path

Portfolio

Revenue Cont.% FY 22

Key Products

3 YR CAGR

Pedia Products

~60%

Tedibar : Low Ph bathing bar for Atopic Dermatitis Atogla Lotion & Cream : Emollients for Atopic Dermatitis Spoo : Rx Driven shampoo for cradle cap

Acne/Face care

Hair/Scalp care

~20%

~12%

Tracnil : Therapy resistant acne, excessive hair due to PCOS Acnemoist : Dryness of skin caused by acne medications Clinmiskin : Antibiotics used for treatment of acne Fash : Purifying face wash for sensitive skin

Perlice : Lice infestation treatment Proanagen : Hair thinning /Shedding face by women Noskurf : Anti dandruff long contact lotion

17%

15%

9%

Source: Company information, data as per company’s sales data

Torrent enters into the Top league in Dermatology

RANK

CORPORATE

Leadership

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

18

21

DERMA

GSK

GLENMARK

SUN*

HEGDE & HEGDE

ABBOTT*

DR. REDDYS

MANKIND

ZYDUS*

WIN-MEDICARE

TORRENT+CURATIO

MACLEODS

INTAS

CIPLA

USV

GALDERMA

CURATIO

TORRENT

• Torrent will be ranked 10th in Derma therapy • Amongst top 5 Rx players amongst Dermatologist

Leveraging Curatio’s equity

• Concept selling through strong Medico Marketing • Cosmetology driven portfolio in sync with TPL derma

portfolio

Leveraging Torrent’s equity

• Existing national prescriber equity • Emphasis on In Clinic effectiveness

E-commerce business model

• Learnings from Curatio to be leveraged for TPL derma portfolio

Source: AIOCD MAT June’22

Enhances Torrent’s presence in high growth high value TA’s of the market

Therapy Rank (Val)

Therapy

Torrent

---

1

3

9

5

4

7

8

10

2

IPM

CARDIAC

GI

CNS

VMN

AD (wo Ins)

PAIN

DERMA

GYNAE

A.I

8

2

4

4

4

9

8

21

17

21

Torrent + Curatio 7

Torrent Strength √ √ √

2

4

4

4

9

8

10

17

21

√ √ √ √

√ √ √ √

√ √ √ √

√ √ √ √

√ √ √

√ √ √

√ √ √

√ √

Torrent will strengthen its position to enter top 5 corporates amongst dermatologist

Source: AIOCD MAT Aug’22

Thank You

← All TranscriptsTORNTPHARM Stock Page →